奥法图穆马布用于治疗自身免疫性结节病
Jianian Hu1,2,3, Yongsheng Zheng1,2,3, Chong Sun1,2,3
1Department of Neurology, Huashan Hospital Fudan University, Shanghai, China.
Journal of the peripheral nervous system : JPNS
|January 13, 2025
概括
在24周内,Ofatumumab治疗在自身免疫结节病 (AN) 患者中显示出100%的改善. 这种B细胞消耗疗法提供了一个潜在的更安全和更有效的替代方案,即使对于那些对rituximab无反应的人.
科学领域:
- 神经学 神经学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 自身免疫结节病 (AN) 是一种罕见的神经疾病,需要有效的治疗.
- 目前对AN的治疗选择可能有局限性或对某些患者无效.
研究的目的:
- 评估ofatumumab在治疗自身免疫结节病 (AN) 的疗效和安全性.
- 评估ofatumumab作为对Rituximab耐药的患者的潜在替代品.
主要方法:
- 这是一项开放标签,前性,观察性研究,涉及8名AN患者.
- 奥法图穆马布 (20毫克) 按特定的时间表在24周内进行皮下注射.
- 临床改善是主要终点,次要评估包括神经学得分和生物标志物.
主要成果:
- 在第24周,所有8名患者均取得了确诊的临床改善.
- 在INCAT分数,MRC总分数,cI-RODS,握力和神经传导研究中观察到显著改善.
- 血清神经纤维光链 (sNfL) 和抗偏抗体的减少,以及B细胞枯竭,也被注意到.
结论:
- 在24周内以20毫克皮下注射的Ofatumumab治疗有效治疗自身免疫性结节病.
- 该疗法表现出良好的安全性,没有报告严重不良事件.
- 奥法图马布为AN患者提供了一种方便,更安全和更有效的替代方案,包括那些对rituximab没有反应的人.
关键词:
慢性炎症性去美色化多基原核隆性神经病变.的一个atumumab.周围神经病变 (Peripheral Neuropathy) 是一种神经病变.前性观察性研究是指前性观察性研究.治疗治疗治疗治疗治疗治疗更多相关视频
相关概念视频
Autoimmune Disorders
385
Autoimmune diseases are a group of disorders in which the body's immune system mistakenly attacks its own cells, tissues, and organs. This results from an overactive immune response against substances and tissues normally present in the body. Let's delve into the concept and mechanism of autoimmune diseases from an immune system point of view, explore different causes and examples of such diseases, and discuss potential solutions.
Concept and Mechanism of Autoimmune Diseases
The immune...
Concept and Mechanism of Autoimmune Diseases
The immune...
385
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
114
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
114
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
141
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
141
Treatment Resistant Cancers
3.2K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.2K
Tumor Immunotherapy
469
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
469
Myasthenia Gravis: Overview and Treatment
1.2K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.2K

![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)
